Medidata’s NEXT SEOUL 2023 Conference Presents Strategies for Successful New Drug Development

• Discussed strategies for innovating clinical trials to improve the global competitiveness of the pharmaceutical industry by using digital technologies.
• JW Pharmaceutical and Celltrion shared cases of developing new drugs with digital clinical solutions.

Seoul, July 11, 2023 - Medidata, a Dassault Systèmes company, held the NEXT SEOUL 2023 conference at the Grand InterContinental Seoul Parnas on July 11.

This conference was under the theme of “Reboot your New Drug Development with Digital Transformation” to present a paradigm for new drug development using digital technology, decentralized clinical trials (DCT), and AI and discuss key strategies.

Experts in the fields of new drug development, clinical trial research and operation, data management, and digital healthcare participated in this event as speakers and made presentations on the trends and strategies of new drug development under the topics including the importance and solution of trusted clinical trial data, the paradigm and applications of decentralized clinical trials in Korea, the operation of global clinical trials using big data and AI, and digital transformation based on the virtual twin, as well as shared real-world cases and solution demos. Over 550 clinical trial experts from biopharma and medical instrument companies, CROs, and academia, participated in this event.

Anthony Costello, CEO of Patient Cloud, Medidata, Dassault Systèmes, said in his keynote speech on Innovation for a New Era of Research, “Today, clinical trials are becoming more and more complex and sophisticated in line with the development of bioscience and the paradigm of personalized medical services, while the pandemic also accelerated the application of digital technology and a transition into patient-centric practices.” He added, “To adapt to the rapidly changing clinical trial environment, we must go beyond Rave EDC (electronic data capture) and realize technological innovation throughout clinical trials.”

Doo-yeon Cho, senior director of JW Pharmaceutical, emphasized that to accelerate global clinical trials and reinforce data management, it is of the utmost importance to select the right partner like Medidata, which has worldwide experience and supports data integrity. Professor Kyung-sang Yu, Department of Clinical Pharmacology, Seoul National University Hospital, suggested a plan to promote the introduction of decentralized clinical trials, which are suitable for the Korean clinical trial environment. At the same time, Sang-joon Lee, senior vice president of Celltrion and director of the company's Data Science Lab, shared the importance of empowerment using digital transformation (DX) strategies and use cases and benefits, as well as the strengths Celltrion has gained from this together with some future approach.

Through this conference, Medidata showcased its latest solutions, including Rave Companion, which helps send HER (Health Electronic Records) to EDC (Electronic Data Capture) solution easily, eCOA, a patient-centric clinical outcome assessment solution, which is essential in the era of decentralized clinical trials. Also introduced was a Medidata AI solution, which supports FDA regulatory compliance as well as efficient management of sites. The session for BIOVIA, the Dassault Systèmes brand that supports digital transformation in R&D, presented strategies for digital transformation using next-generation R&D solutions and customer success stories.

Claire Biot, Vice President, Life Sciences & Healthcare Industry, Dassault Systèmes, who was the final presenter of the sessions, gave a presentation on how virtual twin technology, which can reproduce various real-world actions and changes in physical properties in virtual environments, can be applied to life sciences and help create sustainable innovations.

“Medidata NEXT SEOUL is a meaningful event at which clinical trials experts come together to present and discuss new directions of new drug development,” said Jae-gu Yoo, Vice President, Korea Sales, Medidata, Dassault Systèmes, “Based on the experience and expertise we’ve built up from reaching more than 30,000 clinical trials, we will continue to strive to provide innovative solutions and services in the entire process of clinical trials. We look forward to helping Korean bio-pharma companies gain global competitiveness through this.”

The content of all the presentations made at the Medidata NEXT SEOUL 2023 will be available on Medidata’s website from July 19 for three days.

###

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.